Alumis Inc. Common Stock

NasdaqGS ALMS

Alumis Inc. Common Stock EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024

Alumis Inc. Common Stock EPS (Diluted) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
NasdaqGS: ALMS

Alumis Inc. Common Stock

CEO Mr. Martin Babler Ph.D.
IPO Date Feb. 22, 2021
Location United States
Headquarters 280 East Grand Avenue
Employees 107
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

StockViz Staff

January 15, 2025

Any question? Send us an email